Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
- Status
- UnknownResults none
- Why it is watched
- non-weight indication: cardiovascular
- Who it enrolls
- age 18 Years to no upper limit; healthy volunteers accepted; excludes diabetes; BMI ≥27 required; conditions: Obesity; Blood Pressure
- Interventions
- Liraglutide 6 MG/ML [Saxenda]; Naltrexone-Bupropion Combination
- Conditions
- Obesity; Blood Pressure
- Phase and size
- Phase 4 · 40 participants
- Dates
- Start 2020-09-08
Primary completion 2022-09-30 - Sponsor
- National and Kapodistrian University of Athens (Other)
- Last checked
- Sep 13, 2026
01Endpoints
What the trial will measure
- Changes in blood pressure3 and 6 months
02Eligibility
Who can take part
Inclusion Criteria: * Age ≥18 years with BMI ≥ 30 kg / m2 or BMI ≥ 27 kg / m2 in the presence of dyslipidemia or hypertension or obstructive sleep apnea or fatty infiltration or prediabetes. Exclusion Criteria: 1. Presence of any clinical contraindications for the administration of liraglutide or bupropion / naltrexone 2. Bariatric surgery 3. Diabetes type 2 4. Active malignancy 5. Medication that affects weight (eg corticosteroids, phenothiazines)
03Change log
Registry changes
No changes recorded since the trial was added.